Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 50 50 KWIKPEN versus NOVOLIN N.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 50 50 KWIKPEN versus NOVOLIN N.
HUMALOG MIX 50/50 KWIKPEN vs NOVOLIN N
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially in skeletal muscle and adipose tissue, and by inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase signaling.
Insulin analog that lowers blood glucose by promoting cellular uptake of glucose, inhibiting hepatic glucose production, and stimulating lipogenesis and protein synthesis.
Subcutaneous injection: individualized dose based on metabolic needs, blood glucose monitoring, and prior insulin therapy. Typically administered within 15 minutes before meals or immediately after meals. Total daily dose: 0.5-1.0 units/kg/day in divided doses. For the mix 50/50, half as basal (intermediate-acting component) and half as bolus (rapid-acting component).
Subcutaneous injection. Typical starting dose for type 1 diabetes: 0.5-1.0 units/kg/day divided into 2 doses (morning and evening). For type 2 diabetes: 10 units once or twice daily, adjusted based on blood glucose levels.
None Documented
None Documented
0.5-1 hour (insulin lispro); terminal half-life is approximately 1 hour. Clinically, the rapid clearance allows for flexible dosing timing relative to meals.
10-12 hours for intermediate-acting insulin, with a peak effect at 2-8 hours and duration up to 24 hours. Terminal half-life in subcutaneous depot is 4-6 hours.
Renal: 60-80% as metabolites; hepatic metabolism accounts for most of the remainder. Fecal excretion is minimal.
Renal: 30-80% of dose excreted as unchanged insulin and metabolites. Biliary/fecal: negligible (<1%).
Category C
Category C
Insulin
Insulin